Geng Meiyu's scientific research achievements include developing the world's first target A? Oligosaccharide 97 1, an anti-Alzheimer's disease drug, was transferred in 2009. ? A platform for screening and systematic pharmacodynamic evaluation of anti-tumor drugs targeting receptor tyrosine kinases c-Met, ALK and FGFR, which integrates molecules, cells and whole animals, was first established in China. JG3, the second heparanase inhibitor in the world, was developed, and its anti-tumor activity was better than that of PI88, the first inhibitor. ? It was found that Pl-g-R was an important marker of early recurrence and metastasis of hepatocellular carcinoma.

I. Introduction

Geng Meiyu, female, was born in August 1963. 1980 is a medical college, medical department and bachelor of medicine of Shandong University; 1986, Master of Pharmacology, Faculty of Medicine, Shandong University; 1993 is a doctor of pharmacy in the Department of Pharmacy, University of Tokyo, Japan. He is also the academic director, researcher and project leader of Shanghai Institute of Pharmacology, China Academy of Sciences; Country? 973? Plan? Research on sugar chemistry and sugar biology? Project chief scientist? National Science Fund for Distinguished Young Scholars? .

Two. holding position

He used to be the executive vice president of China Ocean University School of Medicine, the deputy director of Institute of Marine Medicine and Food, and the chief scientist of 973. He is currently the party secretary, deputy director, research leader and doctoral supervisor of Shanghai Institute of Pharmacology, China Academy of Sciences. He is also a director of the Chinese Pharmacology Society, chairman of the Marine Pharmacology Committee of the Chinese Pharmacology Society, and a member of the Tumor Pharmacology Committee of the Chinese Pharmacology Society. Member of the Anti-cancer Drug Committee of China Anti-cancer Society, and vice chairman of the Marine Drug Committee of China Pharmaceutical Society. He is also the deputy editor-in-chief of Marine Medicine, and the editor-in-chief of acta pharmacologica sinica, J Biol Chem, acta pharmacologica sinica, China Pharmacology Newsletter and Marine Science. ?

Three. Main work

Mainly engaged in the research on the structure and function of sugar chain and the molecular mechanism of marine sugar drugs. In recent years, he has presided over the completion of five projects including the National "863" Plan and the National Natural Science Foundation. At present, he is in charge of the first national "973" plan, the national "863" plan and the national natural fund project in the field of sugar chemistry and sugar biology in China. In recent years, nearly 100 papers have been published, of which 38 papers have been included in SCI. Some achievements have been published in internationally renowned academic journals such as Mol. Pharmacology. Journal of neurochemistry. , glycobiology, AME gastrointestinal, biochemical pharmacy. And biochemistry. Authorized 3 national invention patents and applied for 8 national invention patents. Twenty-six graduate students have been trained.

Geng Meiyu has made great contributions to the world medical field with her scientific research achievements.